tbuckley/cabot-search huggingface dataset:
State of Medicine
Authors: Mike Mitka
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Repeated virus identification in the airways of patients with mild and severe asthma during prospective follow-up
Authors: V. Turchiarelli, J. Schinkel, R. Molenkamp, M. P. Foschino Barbaro, G. E. Carpagnano, A. Spanevello, R. Lutter, E. H. Bel, P. J. Sterk
Journal: Allergy (2011)

To cite this article: Turchiarelli V, Schinkel J, Molenkamp R, Foschino Barbaro MP, Carpagnano GE, Spanevello A, Lutter R, Bel EH, Sterk PJ. Repeated virus identification in the airways of patients with mild and severe asthma during prospective follow-up. Allergy 2011; 66: 1099–1106. Background: Respiratory viruses may persist in the airways of asthmatics between episodes of clinical worsening. We hypothesized that patients with clinically stable, severe asthma exhibit increased and more prolonged viral presence in the airways as compared to mild asthmatics and healthy controls. Methods: Thirty-five subjects (no cold symptoms >4 weeks) entered a 12-week prospective study using three groups: clinically stable mild asthma (GINA 2) (n = 12, age 34.1 ± 13.4 year), severe asthma (GINA 4) (n = 12, age 49.3 ± 14.8 year) and healthy controls (n = 11, age 37.9 ± 14.2 year). All subjects underwent spirometry and completed a written questionnaire on asthma symptoms at baseline. Nasal and throat swabs, induced sputum samples, exhaled breath condensate and gelatine-filtered expired air were analysed at 0, 6 and 12 weeks by a multiplex real-time PCR assay for 14 respiratory viruses using adequate positive and negative controls. Results: Thirty-two of 525 patient assessments (6%) showed a virus-positive sample. Among the 14 respiratory viruses examined, HRV, adenovirus, respiratory syncytial virus, parainfluenza 3&4, human bocavirus, influenza B and coronavirus were detected. When combining all sampling methods, on average 18% of controls and 30% of mild and severe asthmatics were virus positive, which was not different between the groups (P = 0.34). The longitudinal data showed a changing rather than persistent viral presence over time. Conclusion: Patients with clinically stable asthma and healthy controls have similar detection rates of respiratory viruses in samples from nasopharynx, sputum and exhaled air. This indicates that viral presence in the airways of stable (severe) asthmatics varies over time rather than being persistent.
First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013
Authors: A Mailles, K Blanckaert, P Chaud, S van der Werf, B Lina, V Caro, C Campese, B Guéry, H Prouvost, X Lemaire, M  C Paty, S Haeghebaert, D Antoine, N Ettahar, H Noel, S Behillil, S Hendricx, J C Manuguerra, V Enouf, G La Ruche, C Semaille, B Coignard, D Lévy-Bruhl, F Weber, C Saura, D Che, Collective The investigation team
Journal: Eurosurveillance (2013)

In May 2013, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection was diagnosed in an adult male in France with severe respiratory illness, who had travelled to the United Arab Emirates before symptom onset.
SYPHILITIC PAROXYSMAL COLD HEMOGLOBINURIA
Authors: Irvin L. Schweitzer
Journal: Annals of Internal Medicine (1957)

Case Reports1 March 1957SYPHILITIC PAROXYSMAL COLD HEMOGLOBINURIAIRVIN L. SCHWEITZERIRVIN L. SCHWEITZERSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-46-3-590 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptParoxysmal cold hemoglobinuria is a rare hemolytic disorder of which there are two distinct varieties. The syphilitic form is caused by a specific hemolysin which becomes fixed to erythrocytes when the patient is chilled and causes hemolysis when the patient is subsequently warmed. It is almost invariably associated with an inactive phase of late congenital or acquired syphilis. The non-syphilitic form is caused by a high titer of cold agglutinins and is frequently associated with vascular disorders such as the Raynaud syndrome. The following is a case of syphilitic paroxysmal cold hemoglobinuria with three aspects of special interest: (1) it...Bibliography1. Puris AM: Paroxysmal hemoglobinuria, Am. J. Dis. Child. 37: 1027, 1929. Google Scholar2. Hill NP: Syphilitic paroxysmal cold hemoglobinuria causing transfusion reaction: response to penicillin, Am. J. Syph., Gonor. and Ven. Dis. 35: 329, 1951. MedlineGoogle Scholar3. van LoghemMendes de LeonFrenkel-Tietzvan der Hart JJDEHM: Two different serologic mechanisms of paroxysmal cold hemoglobinuria, illustrated by three cases, Blood 7: 1196, 1952. CrossrefMedlineGoogle Scholar4. SussmanKayden RMHJ: Renal insufficiency due to paroxysmal cold hemoglobinuria, Arch. Int. Med. 82: 598, 1948. CrossrefGoogle Scholar5. Becker RM: Paroxysmal cold hemoglobinuria, Arch. Int. Med. 81: 630, 1948. CrossrefGoogle Scholar6. JordanProutyHeinleDingle WSRLRWJJ: The mechanism of hemolysis in paroxysmal cold hemoglobinuria. III. Erythrophagocytosis and leukopenia, Blood 7: 387, 1952. CrossrefMedlineGoogle Scholar7. Hall BD: Paroxysmal cold hemoglobinuria, U. S. Armed Forces M. J. 3: 1519, 1952. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication September 21, 1955.From the 5th General Hospital.Requests for reprints should be addressed to Major Irvin L. Schweitzer (MC), 222 W. Exchange Street, Freeport, Illinois. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByParoxysmal cold haemoglobinuria 1 March 1957Volume 46, Issue 3Page: 590-594KeywordsAgglutininsBlood plasmaCongenital syphilisHemoglobinLeukocytosisNeutropeniaRaynaud syndromeSyphilis Issue Published: 1 March 1957 PDF DownloadLoading ...
The Biomarker Nt-pro-BNP Substantially Improves Prediction of Death and First Major Cardiovascular Events in Primary Care Subjects: Results From the DETECT Study
Authors: David Leistner, Jens Klotsche, Lars Pieper, Gunter K Stalla, Hendrik Lehnert, Sigmund Silver, Winfried Marz, Hans-Ulrich Wittchen, Andreas M Zeiher
Journal: Circulation (2009)
Life-threatening Complications From Doxorubicin-Docetaxel Chemotherapy for Breast Cancer—Reply
Authors: Etienne G. C. Brain, Thomas Bachelot, Daniel Serin
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alternatively activated macrophages and impaired phagocytosis of S. aureus in chronic rhinosinusitis
Authors: O. Krysko, G. Holtappels, N. Zhang, M. Kubica, K. Deswarte, L. Derycke, S. Claeys, H. Hammad, G. G. Brusselle, P. Vandenabeele, D. V. Krysko, C. Bachert
Journal: Allergy (2010)

To cite this article: Krysko O, Holtappels G, Zhang N, Kubica M, Deswarte K, Derycke L, Claeys S, Hammad H, Brusselle GG, Vandenabeele P, Krysko DV, Bachert C. Alternatively activated macrophages and impaired phagocytosis of S. aureus in chronic rhinosinusitis. Allergy 2011; 66: 396–403. Abstract Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by biased Th2 inflammation and CRS without nasal polyps (CRSsNP) by a Th1 immune response. Colonization by Staphylococcus aureus is increased in CRSwNP. We aimed to determine macrophage phenotypes in nasal mucosa of CRSwNP and CRSsNP and to examine phagocytosis of S. aureus in these pathologies. Methods: Macrophage phenotyping was performed by immunohistochemical staining on nasal mucosa sections from 28 patients; in addition flow cytometry analysis was performed. Tissue homogenate protein levels of IFN-γ, IL-5, IL-6, IL-1β, TGF-β, eosinophil cationic protein (ECP) and total IgE were analyzed and correlated with macrophage subtypes. Phagocytosis of S. aureus was analyzed by flow cytometry. Survival of S. aureus in Thp1 cells in the presence of polarizing cytokines was studied in vitro. Results: By immunohistochemical analysis more M2 macrophages were present in CRSwNP than in CRSsNP. This also was positively correlated with increased levels of IL-5, ECP and locally produced IgE and decreased levels of IL-6, IL-1β and IFN-γ. FACS analysis of dissociated nasal tissue confirmed the presence of increased numbers of M2 macrophages (CD206+HLADR+CD14+CD11c+CD20−) in CRSwNP as compared to controls, while the number of M1 macrophages (CD206−HLADR+CD14+CD11cintCD16−CD20−) was not different. Phagocytosis of S. aureus by human tissue derived macrophages was reduced in CRSwNP as compared to macrophages from the control inferior turbinates. Conclusions: Decreased phagocytosis of S. aureus and an M2 activation phenotype in CRSwNP could potentially contribute to persistence of chronic inflammation in CRSwNP.
Evaluation of antitumor activity, anti-angiogenic activity and pharmacodynamic end points for orally active multi-targeted anti-angiogenic kinase inhibitors targeting c-MET, ron, VEGF and Tie-2 receptors
Authors: Hannah Nguyen, Normand Beaulieu, Annie Barsalou, Carole Beaulieu, Ian Chute, Isabelle Dupont, Julien Durand, Serge Gravel, Rowena Law, Marie-France Robert, Sylvain Lefebvre, Stephen Claridge, Franck Raeppel, Oscar Saavedra, Naomy Bernstein, Marie-Claude Granger, Lijie Zhan, David Llewellyn, Amal Wahhab, Robert Deziel, James Wang, Jeffrey M. Besterman, Arkadii Vaisburg, A. Robert Macleod
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

246 

Overexpression of the c-MET receptor tyrosine kinase and its ligand, the hepatocyte growth factor (HGF), have been associated with the development and poor prognosis of a number of human cancers. Most notably, germline missense mutations in the c-MET receptor are the causal event in hereditary papillary renal cell carcinoma (HPRC). In addition to its role in tumor cell survival and metastasis, c-MET is also implicated in angiogenesis and has been shown to cooperate synergistically with the vascular endothelial growth factor receptors (VEGFRs). Thus, the combined inhibition of c-MET and VEGF signaling represents a promising approach to cancer treatment by targeting multiple pathways involved in angiogenesis as well as tumor cell survival directly. We have identified a series of novel small molecule inhibitors with potent activity against the c-MET receptor and all three receptors of the VEGFR family. Lead molecules in this series also have significant activity against other therapeutically relevant kinases including Ron, Tie-2 and FLT-3. Profiling in tumor cell lines shows that the lead molecules potently inhibit HGF-dependent and constitutive c-MET phosphorylation, and c-MET-dependent phenotypes such as HGF-stimulated cell scattering and migration. Importantly, these molecules also significantly suppress the growth of tumor cells in which c-MET is constitutively active. Lead molecules exhibit potent activity in in vitro angiogenesis assays (endothelial tubule formation). The lead compounds show broad spectrum anti-tumor activity with no associated body weight loss or marrow suppressive effects. In addition, we have evaluated the activity of these inhibitors on several pharmacodynamic endpoints including c-MET and Tie-2 phosphorylation in tumors of treated animals, and VEGFR2/KDR and ERK phosphorylation in the lung of treated animals. The activity against these pharmacodynamic endpoints demonstrates a correlation between inhibition of angiogenesis and antitumor activity in several xenograft models.
Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy
Authors: Uwe Michl, Pierre Tennstedt, Lena Feldmeier, Philipp Mandel, Su J. Oh, Sascha Ahyai, Lars Budäus, Felix K.H. Chun, Alexander Haese, Hans Heinzer, Georg Salomon, Thorsten Schlomm, Thomas Steuber, Hartwig Huland, Markus Graefen, Derya Tilki
Journal: European Urology (2015)
Abstract 19868: Mirna-17-3p Controls Exercise-induced Cardiac Growth
Authors: Jing Shi, Qinkao Xuan, Wei Sun, Yue Ji, Hui Wang, Siyi Fu, Junjie Xiao, Xiangqing Kong
Journal: Circulation (2014)

Aims: Endurance exercise has been proved to be a stimulus for cardiac growth and it can induce cardiac hypertrophy and cardiomyocyte proliferation. Although genes and transcriptional factors responsible for that has been well-established, little is known about the potential role of microRNAs (miRNAs, miRs) in this physiological process. The miR-17-92 cluster has been reported to promote cell proliferation and play anti-apoptotic roles in tumor cells. This study aims at investigating the role of miR-17-92 cluster or its member in exercise-induced cardiac growth. Methods: Endurance exercise was induced by swimming the mice for 3 weeks. Using quantitative reverse transcription polymerase chain reactions (RT-PCRs), members in miR-17-92 clusters were determined and miR-17-3p was found to be significantly up-regulated. The expression levels of miR-17-3p in ventricular tissue of mice subjected to transaortic constriction (TAC) and DCM patients were also determined using RT-PCRs. In cultured cardiomyocytes, the e...
The autocrine sPDZD2 protein is a potential p53 activator
Authors: Chun Tam, Vincent Liu, Wai Leung, Kwok-Ming Yao, Stephen Shiu
Journal: Clinical Cancer Research (2007)

B40   PDZ domain containing protein 2 (PDZD2) is a ubiquitously expressed six-PDZ domain protein of largely undefined functions. It is cleaved by caspase-3 to form a secreted PDZ domain containing protein 2 (sPDZD2). The sPDZD2 protein has been proposed to function as a potential autocrine prostate tumor suppressor. In this study, we investigated the effects of sPDZD2 on the growth of human prostate, breast and liver cancer cells. The sPDZD2 protein was found to induce senescence of prostate cancer DU145 cells, quiescence of breast cancer MCF-7 and liver cancer Hep-G2 cells, via transcriptional activation of mutant or wild-type p53. Our results indicate that sPDZD2 is worthy of further development as a novel p53 activator for cancer therapy.
Out of hours vs standard working hour care; a retrospective comparison of pneumonia care
Authors: Luke Harding, Edward Davies, Ram Sundar, Imran Aziz
Journal: European Respiratory Journal (2014)

Background : It is widely assumed that Out of hours (OOH) care is inferior to that given during the standard working hours (SWH) of 9-5 Monday to Friday.   Aims and Objectives : We aimed to establish whether there was a difference in the care received by pneumonia patients by looking into patients admitted with community acquired pneumonia (CAP) and hospital acquired/aspiration pneumonia (non-CAP) during SWH and OOH.   Methods : We undertook a retrospective audit into the initial management of patients admitted to our hospital with a primary diagnosis of CAP and non-CAP, and died during their hospital stay over a 9 month period. We assessed the quality of care by asking 3 key questions; a) Was severity assessment (CURB65 in CAP patients) documented? b) Was an appropriate initial antibiotic, based on hospital formulary, prescribed? c) What was the length of stay (LOS) before demise?   Results : 148 patients mean (range) age 80.2 (40-101) died of pneumonia , out of which 89 had CAP and 59 non-CAP. The other results are shown in table 1.   Conclusions : Adherence to antibiotic prescription for CAP was poor for both SWH and OOH, as most patients were treated for non-CAP sepsis. Severity assessment for CAP is less likely OOH, however this does not translate into a decreased adherence to our antibiotic formulary or survival time. Extra effort should be made to train juniors at the front-end of the hospital ie. A&Es and acute medicine departments to adhere to antibiotic policy in all patients with CAP.
Drug induced lung disease: 11 cases
Authors: Elif Kupeli, Tugce Sahin Ozdemirel, Zeynep Erayman Ozen, Gaye Ulubay, Sule Akcay, Fusun Oner Eyuboglu
Journal: European Respiratory Journal (2011)

Drug induced lung disease (DILD) is the most common cause of iatrogenic damage to the lungs. More than 350 drugs have been identified leading to DILD. We evaluated the characteristics of patients with DILD between 2007-2010, at our institution retrospectively, for demographic features, pulmonary function tests (PFT), diffusion capacities, high resolution computed tomograms (HRCT) findings, diagnostic methods and treatment modalities. 11 patients (M:F=9:2, mean age 60±20.3) were identified with DILD. 3 had chronic myeloid leukemia; congestive heart failure, asthma, testicular cancer, malignant melanoma, acute lymphocytic and myelocytic leukemia, renal transplantation and lung cancer was diagnosed in one patient each. Cough, respiratory failure and fever were the most common symptoms. 4 patients exhibited normal, 5 revealed restrictive, one patient for each revealed obstructive and mixed PFTs. Diffusion capacities in 6 patients were low. Ground glass opacities (2), bilateral patchy consolidation (2), interstitial fibrosis (2), pleural effusion (1) were evident in HRCT, however 1 patient revealed no abnormality. 3 patients underwent bronchoscopy for bronchoalveoler lavage. Infectious causes were excluded by microbiological and laboratory tests. Lung involvement was thought to be due to bleomycine (1), methotrexate (1), cyclophosphamide (1), cisplatin (1), dasatinib (2), Ara-C (2), cilazapril (1), amiodaron (1), tacrolimus (1). Radiological and clinical improvement was achieved with systemic steroids in 10 and cessation of the drug in one. DILD can cause significant mortality and morbidity. We believe that consequence of DILD could be reduced by high degree of suspicion and by excluding other causes for common pulmonary symptoms and abnormal radiographic findings.
Abstract 4528: Comparison of anti-proliferation activity of BEZ 235, a multi-step inhibitor of mTOR pathway, vs. BKM120, a pan PI3K inhibitor, in lung cancer cell lines (LCCL)
Authors: Chao H. Huang, Christopher Beaudoin, Peter Van Veldhuizen, Faris Farassati
Journal: Cancer Research (2014)

Abstract Background: PI3K/AKT/mTOR(Mammalian target of rapamycin) signal transduction pathway is over-activated in many cancers including lung cancers. The activation of cell surface receptors i.e.EGFR (Epidermal Growth Factor Receptor) signals through PI3K/AKT/mTOR pathway which then results in increase cell proliferation, angiogenesis and anti-apoptosis process. BEZ 235 is a multi-step inhibitor of PI3K and mTORC 1 / 2. BKM 120 is a novel pan class I PI3K inhibitor of all class I PI3K isoforms (α, β, Υ, δ). Inhibition of multiple steps of PI3K/AKT/mTOR pathway would be advantageous and could yield higher activity and overcome over activation of PI3K/AKT, a potential mechanism of resistance to mTOR inhibitors. Docetaxel (D) is an approved agent used in the treatment of lung cancer. We previously demonstrated that the sequence of D followed by mTOR inhibitor temsirolimus (T) in lung cancer cell lines (LCCL) had increased suppression of cell proliferation as compared to reverse sequence of T→D due to suppression of over-activation of PI3K/AKT resistance mechanism. We studied the anti-proliferation effect of each compound in LCCL and also compared the activity of sequential docetaxel followed by BKM 120 vs. D followed by BEK235. Methods: Adenocarcinoma LCCL H2122 and A549 were treated with increasing concentrations of BEZ 235 (50nM, 75 nM, 100 nM) and BKM 120 at same concentrations. Both agents were provided by Novartis.We assessed the cell proliferation by optical density. In the sequential treatment study, we incubated LCCL with D 100nM for 24h then added BKM 120 or BEZ235 at 50nM, 75nM and 100nM. We then assessed the anti-proliferation effect at 48h and 72h. Results: BEZ 235 single had greater inhibitory effect in LCCL proliferation as compared to BKM120. The sequential treatment of D followed by BEZ235 or BKM120 did not yield higher anti-proliferation effect compared to single agent treatment in both LCCL. Conclusion: Single agent BEZ235 had greater anti-proliferation effect than BKM120 in both LCCL. The sequential treatment of D followed by BEZ235 or BKM120 did not lead to increased anti-proliferation effect. The potential explanation of lack of synergistic effect may due to suppression of PI3K by pretreatment with D. Note: This abstract was not presented at the meeting. Citation Format: Chao H. Huang, Christopher Beaudoin, Peter Van Veldhuizen, Faris Farassati. Comparison of anti-proliferation activity of BEZ 235, a multi-step inhibitor of mTOR pathway, vs. BKM120, a pan PI3K inhibitor, in lung cancer cell lines (LCCL). [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4528. doi:10.1158/1538-7445.AM2014-4528